A recent preprint paints a grim picture of the effect of role of obesity in COVID-19 infection. A high role of C-reactive protein (CRP) is specifically indicated as a risk for critical illness.
It is possible to reduce the level of CRP by statin administration, but statin administration raises the level of ACE2. It is not known whether that increases or decreases the risk from the virus. The use of statins for coronavirus patients has been suggested - so has the possibility of the discontinuation of statin use by infected patients.
Obviously I would hope to see a study of statin use in COVID-infected patients, and one does begin recruiting this month. The entry, however, says that it will be completed in August 2021. My thought is that surely somebody could run around the New York COVID wards with a clipboard, though I'd hope for a wiser way to do this, asking patients whether they use statins versus whether they have ever turned down the suggestion of taking statins when their doctor mooted the issue, and seeing how many of which group ended up in the ICU. What are the factors preventing data like this, which could have such influence on the way people respond to the outbreak, from being collected and published within a couple of weeks?